GILEAD SCIENCES, INC. |
Market Closed -
Other stock markets
|
Pre-market 07:01:00 am | |||
| 63.94 USD | -2.65% |
|
63.78 | -0.26% |
Financials (USD)
| Sales 2024 * | 27.61B | Sales 2025 * | 27.99B | Capitalization | 79.66B |
|---|---|---|---|---|---|
| Net income 2024 * | 403M | Net income 2025 * | 6.35B | EV / Sales 2024 * | 3.54 x |
| Net Debt 2024 * | 18.15B | Net Debt 2025 * | 12.68B | EV / Sales 2025 * | 3.3 x |
| P/E ratio 2024 * |
190
x | P/E ratio 2025 * |
12.4
x | Employees | 18,000 |
| Yield 2024 * |
4.85% | Yield 2025 * |
5.07% | Free-Float | 99.89% |
More Fundamentals
* Assessed data
More news
Latest transcript on Gilead Sciences, Inc.
More recommendations
More press releases
| 1 day | -2.65% | ||
| 1 week | -4.98% | ||
| Current month | -1.93% | ||
| 1 month | -2.26% | ||
| 3 months | -12.05% | ||
| 6 months | -14.19% | ||
| Current year | -21.07% |
1 week
63.74
67.63
1 month
63.7468.37
Current year
63.7487.87
1 year
63.7487.87
3 years
57.1789.74
5 years
56.5689.74
10 years
56.56123.37
| Managers | Title | Age | Since |
|---|---|---|---|
Daniel O'Day
CEO | Chief Executive Officer | 59 | 19-02-28 |
Andrew Dickinson
DFI | Director of Finance/CFO | 54 | 15-12-31 |
Flavius Martin
CTO | Chief Tech/Sci/R&D Officer | - | 21-04-11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Anthony Welters
BRD | Director/Board Member | 69 | 20-10-16 |
| Director/Board Member | 71 | 17-12-31 | |
Ted Love
BRD | Director/Board Member | 65 | Jan. 31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 13.99% | 254 M€ | +12.51% | - | |
| 8.10% | 0 M€ | 0.00% | - | |
| 8.06% | 0 M€ | 0.00% | - | |
| 5.23% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-28 | 63.94 | -2.65% | 5,593,404 |
| 24-05-24 | 65.68 | -0.74% | 5,971,044 |
| 24-05-23 | 66.17 | -2.40% | 5,625,302 |
| 24-05-22 | 67.8 | +0.76% | 6,227,702 |
| 24-05-21 | 67.29 | -0.90% | 5,701,228 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotes
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
63.94
USD
Average target price
82.77
USD
Spread / Average Target
+29.46%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -21.07% | 79.66B | |
| +38.59% | 727B | |
| -7.89% | 347B | |
| +15.66% | 319B | |
| +0.24% | 274B | |
| +13.14% | 238B | |
| +7.12% | 204B | |
| -6.42% | 203B | |
| +4.23% | 161B | |
| -1.70% | 160B |
- Stock Market
- Equities
- GILD Stock
